Sarepta's Most Polarizing CEO Is Walking Away. Here's What He Left Behind.

When Gene Therapy Gets Dangerous

Elevidys eventually received traditional approval for ambulatory patients (those who can still walk) aged four and older, plus accelerated approval for non-ambulatory patients. It looked like a triumph. Revenues surged.

Then things got dark.

In June 2025, Sarepta's ex-U.S. partner Roche paused dosing for non-ambulatory patients after two fatal cases of acute liver failure among roughly 140 treated patients in that group. The company discontinued commercial use of Elevidys in non-ambulatory patients entirely. Ambulatory patients could still receive the therapy, but the damage was done.

By July 2025, the FDA was raising its own alarm bells about liver injuries linked to Elevidys. The agency requested a shipment pause and slapped a boxed warning, the most serious kind, on the drug. One source described the path to resuming broad U.S. sales as "arduous and treacherous."

The stock cratered. Sarepta cut 500 jobs and halted several limb-girdle muscular dystrophy gene therapy programs. Shares dropped another 4% in after-hours trading the night Ingram announced his departure.

It Got Personal

Ingram didn't just cite the usual "spend more time with family" line. His reason was painfully specific: his wife and son were recently diagnosed with myotonic dystrophy type 1 (DM1), a different form of muscular dystrophy. Sarepta happens to be developing a DM1 treatment, SRP-1003, an siRNA therapy currently in Phase 1/2 trials through a partnership with Arrowhead Pharmaceuticals.

The man who spent a decade fighting for DMD patients now has the disease he's been circling in his own home. It's the kind of detail that makes you pause, regardless of how you feel about his track record.

What's Left in the Medicine Cabinet

Sarepta isn't just Elevidys, though. The next CEO will inherit a sprawling pipeline that stretches well beyond Duchenne. The company has siRNA programs, a different technology that silences disease-causing genes, targeting Huntington's disease (Phase 1 starting Q2 2026), as well as earlier-stage work in conditions like facioscapulohumeral muscular dystrophy and spinocerebellar ataxia.

And those LGMD gene therapy programs that were paused? Some readouts are still expected.

Financially, Sarepta ended Q4 2025 with roughly $954 million in cash and is guiding for $1.2 to $1.4 billion in 2026 revenue. The company says it's on track for cash-flow positivity and non-GAAP profitability this year. Whether that holds depends heavily on whether Elevidys can claw back momentum in ambulatory patients while the non-ambulatory market remains off-limits.

There's also a bright spot overseas: Elevidys launched commercially in Japan through partner Chugai Pharmaceutical, triggering a $40 million milestone payment. Over 1,200 patients have been treated globally with the therapy, and long-term data from the Phase 3 EMBARK study continues to show motor function improvements sustained over two to three years in ambulatory boys.

A Sector at a Crossroads

Ingram's departure lands at a moment when the entire gene therapy sector is soul-searching. Biotech initial funding plummeted from $2.6 billion in Q1 2025 to just $900 million in Q2. The FDA is losing critical expertise; a 19% workforce reduction has hit gene editing reviewers particularly hard. Manufacturing costs remain stubbornly high, and building a new facility that meets U.S. regulatory standards takes five to ten years.

Meanwhile, payers are demanding more real-world evidence before they'll cover therapies that cost millions per dose. The promise of gene therapy — one treatment, one cure — is still alive, but the business model around it is struggling to keep up.

The Verdict

Doug Ingram was a bulldozer. He pushed drugs through regulatory barriers that others might have accepted as immovable. He gave families hope when the standard answer was "there's nothing we can do." He also presided over safety disasters, shareholder destruction, and an approach to FDA engagement that made plenty of scientists uncomfortable.

His successor will need to be part scientist, part diplomat, and part turnaround artist. They'll inherit a company with real revenue, a deep pipeline, and a brand that's simultaneously beloved by the patient community and distrusted by regulators.

Good luck with that job posting.

Half a Billion for a Pill That Doesn't Exist Yet

Boehringer Ingelheim just dropped $500 million on a preclinical pill from a tiny Oxford biotech, and it's not the only massive immunology deal they've inked lately. The race to replace autoimmune injections with oral therapies is getting very expensive, very fast.